Context Therapeutics is trading 5.4% down at $0.30, with no clear company-specific catalyst identified for the September 30, 2026 decline.
- The latest company announcement located was September 9, when it reported the first patient dosed in its CT-202 Phase 1 trial; that earlier update does not explain the decline.
- Supplied broader-market indicators are mostly positive and do not clearly account for the move.